// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Transfusion in the outpatient setting ‐ a plan for each patient

S.M. Vora - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Fatal acute haemolytic transfusion reaction due to Anti Wright (a) antibody

R. Chengal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute haemolytic transfusion reaction

N/A

The Impact of Vacuum‐Packaging on Fresh Frozen Plasma Dry Thawing Time

M. Hazell - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Complete Remission with Incomplete Count Recovery (CRi) Prior to Allogeneic Haematopoietic Cell Transplantation for Acute Myeloid Leukaemia is Associated with a High Non‐relapse Mortality without Increased Relapse Risk

A. Innes - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Donor Selection: A Scottish Experience

H. Hunter - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Erythropoietic Stimulating Agents for Pure Red Cell Aplasia Following Major ABO Mismatch T‐deplete Allogeneic Stem Cell Transplants

V. Mehra - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myeloid neoplasms

Rituximab

Post‐transplant flow cytometry MRD predicts relapse in AML and high risk MDS patients treated with allogeneic haematopoietic stem cell transplant

H. Wood - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute promyelocytic leukemia

Vidaza

T Cell Replete Haploidentical Transplantation for Haematological Malignancy; Experience from the Scottish Adult Allogeneic BMT Service

A. Kanny - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

Cyclophosphamide

Evaluation of Allogeneic Stem Cell Transplant patients’ physical function & quality of life from pre‐assessment to day 100, within the National Stem Cell Transplant Unit

J. Simcock - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

Obesity in Survivors of Childhood Acute Lymphoblastic leukaemia

A. Mathew - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Obesity

Dexamethasone

Vertebral abnormalities on imaging and back pain in children: consider haematological malignancy even when the full blood count is normal

A. Rose - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hodgkin's Lymphoma

N/A

Acute Promyelocytic Leukaemia Presenting as Acute Myocardial Infarction

B. Salhan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute promyelocytic leukemia

Fibrinogen (IV)

Dental implications of haematological conditions – a patient's journey

A.S. Dhadwal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dental and Oral Health

Acute myelocytic leukemia

N/A

The impact of the BSH 2018 polycythaemia vera guidelines on clinical management in the Sheffield and Barnsley catchment area

S. Francis - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Essential thrombocythemia

Hydroxycarbamide

Attacking Infection When the Defences Are Down: An Audit of the Management of Sepsis in Haemato‐oncology Patients in a Tertiary centre

P. D'Arienzo - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Neutropenia

Piperacillin/tazobactam

A Re‐audit of Reducing Preventable Admissions and Transfusion Delays for Haematology Patients Receiving Red Cell Transfusion in the Combined Day Unit at Royal Derby Hospital

J. Ryan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improving the Door to Needle Time for Neutropenic Sepsis Patients in ED

A. Mandal - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Neutropenic Sepsis

N/A

A regional audit of clinic consultation times

N.W.B. Hubble - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Audit on NICE Technological Guidance regarding Azacitidine for high IPSS Myelodysplastic Syndrome

Z.J. Ang - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Myelodysplastic Syndrome

Erythropoietin

Glycosylated haemoglobin ‐ a false sense of security

E. Finan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hereditary spherocytosis

N/A

Copyright © 2026. QuantiNova All rights reserved